Call customer care on: 0333 358 0200
Dr Ruch Karunadasa

Authored on 24 January 2024 by Dr Ruch Karunadasa,

Reviewed 24 January 2024 by Dr Adeel Arshad.

Understanding GLP-1/GIP: A Guide to Dual-Action Weight Loss Treatments

What is GLP-1 / GIP

A groundbreaking treatment is making waves in the UK, offering new solution options for individuals with type 2 diabetes and obesity aiming for substantial weight reduction.

Tirzepatide stands out as a pioneering medication by targeting two specific receptors: the glucose-dependent insulinotropic polypeptide (GIP) and the glucagon-like peptide-1 (GLP-1) receptor, facilitating significant weight loss in patients.

More well-known medications like Semaglutide focus on a single receptor. This raises the question: how do Tirzepatide and Semaglutide differ and what does the targeting of receptors GIP and GLP-1 do?

What is GLP-1

GLP-1, or glucagon-like peptide-1, is a hormone integral to appetite regulation and insulin secretion. Leveraging this pathway, treatments can effectively curb hunger and enhance satiety, ultimately reducing caloric intake.

What is GIP

GIP, or glucose-dependent insulinotropic polypeptide, plays a pivotal role in blood sugar regulation and fat metabolism. It's key in encouraging fat reduction and preventing fat accumulation, positioning it as a critical component in weight management strategies.

Introducing Mounjaro: A Dual-Action Approach

Mounjaro represents a revolutionary treatment that targets both the GLP-1 and GIP pathways. This dual-action strategy not only moderates appetite but also modulates body fat utilisation. These improvements can reduce the risk of heart disease, kidney disease , forms of fatty liver disease as well as type 2 diabetes. With the synergistic effects of GLP-1 and GIP agonists, Mounjaro delivers a holistic approach to weight management.

What is best? GLP-1 Alone vs GLP-1/GIP Combination

Currently, there are no direct comparison trials published. However, when analysing clinical trials for both GLP-1/GIP treatments and GLP-1 only treatments, patients receiving GLP-1/GIP alongside diet and lifestyle changes achieved a 20.9% weight loss at 72 weeks, compared to a 14.9% weight loss at 68 weeks for those on GLP-1 only treatments.

The choice between GLP-1 alone and GLP-1/GIP combination treatments depends on individual needs and medical advice. To check your eligibility, click here.

PrivateDoc weight loss programme

Our programme combines weight loss medication with tailored diet guides and lifestyle coaching.

  • Breakthrough weight loss medication
  • Monthly meal plans
  • 12 week coaching plan
  • Private community access
  • Ongoing medical support

How it works

Get personalised care
02. Get personalised care

We'll provide you with a tailored treatment plan from a UK registered doctor

Get next day delivery
03. Get next day delivery

Receive genuine medication shipped discreetly to your door

Did you know?

Over 40% of the population has tried to lose weight at some point in the last 5 years – so you’re certainly not alone